Antimalarial drug discovery and design in the Era of resistance
Citation:
Bell, A., Antimalarial drug discovery and design in the Era of resistance, Current Pharmaceutical Design, 19, 2, 2013, 264-265Download Item:
Bell 2013 CPD Editorial.pdf (Published (author's copy) - Peer Reviewed) 94.63Kb
Abstract:
These are interesting times for antimalarial drug research. On the one hand, recent reports from Southeast Asia
paint a grim picture of reduced malarial parasite susceptibility to artemisinin combination therapies (ACTs),
currently the mainstay of antimalarial treatment in most of the world [1]. History has shown us that the
protozoal parasite of malaria (Plasmodium), in particular the most lethal human parasite Plasmodium
falciparum, is adept at acquiring resistance to the antimalarial drugs that we have deployed [2]. The fall from
grace of former stalwarts such as chloroquine and sulphadoxine + pyrimethamine has in this respect been
spectacular: in some regions the therapeutic lifespan of the latter has been as little as 5 years [3].
Author's Homepage:
http://people.tcd.ie/abellDescription:
PUBLISHED
Author: BELL, ANGUS
Type of material:
Journal ArticleCollections:
Series/Report no:
Current Pharmaceutical Design19
2
Availability:
Full text availableKeywords:
editorialDOI:
http://dx.doi.org/10.2174/1381612811306020264Licences: